Products That Count unveils the winners of the Q4 2025 Product Awards, celebrating standout products across Human-Centered Design, IoT, and other verticals.SAN FRANCISCO, Dec. 17, 2025 /PRNewswire-PRWeb/ -- Products That Count, the most trusted source for product leadership insights and a global network of over 600,000 product managers and executives, today announced the winners of the 2025 Q4 Product Awards. Now in its eighth year, the Product Awards recognize the tools and teams enabling product leaders t ...

Johnson & Johnson (NYSE:JNJ) is included among the 12 Best Dogs of the Dow to Invest in. BofA Sees J&J’s Premium Multiple as Justified On December 15, BofA raised its price target on Johnson & Johnson (NYSE:JNJ) to $220 from $204. The firm kept a Neutral rating. The firm says J&J’s premium multiple “looks appropriate for its growth plus asset mix.” It is now valuing the stock based on a new FY27 EPS estimate. Johnson & Johnson (NYSE:JNJ) has already had a big year. Shares are up more than 45% in 2025. H ...

Core Insights - Elon Musk's net worth has reached a record $648 billion, with a year-to-date gain of $216 billion, surpassing the entire fortune of LVMH CEO Bernard Arnault [1][2] - Tesla's stock price closed at an all-time high of $490, significantly contributing to Musk's wealth increase, alongside a doubling of SpaceX's valuation to $800 billion [2][5] - Musk's wealth is more than double that of the second richest individual, Larry Page, and exceeds the market values of major companies like Oracle and Mastercard [3][4] Company Performance - Tesla's stock has seen a remarkable recovery, with a significant rally following a period of decline earlier in the year, driven by investor optimism regarding AI and autonomous vehicle development [5][6] - The approval of Musk's pay package by Tesla shareholders could potentially make him the world's first trillionaire if he meets specific performance milestones [8] Industry Trends - The surge in stock prices for Tesla and other major tech companies is largely attributed to the excitement surrounding AI advancements, with Musk investing heavily in AI for Tesla's products [6][7] - Key shareholders in the AI sector, including Musk, have experienced substantial wealth gains, reflecting the broader market trends influenced by AI developments [7]

Group 1 - The core viewpoint of the article is that the Royal Bank of Canada has raised the target price for Johnson & Johnson from $230 to $240 [1] Group 2 - The adjustment in the target price reflects a positive outlook on Johnson & Johnson's performance and potential growth [1]

Core Insights - The State Street Health Care Select Sector SPDR ETF (XLV) is a passively managed ETF launched on December 16, 1998, providing broad exposure to the Healthcare - Broad segment of the equity market [1] - XLV is the largest ETF in its category, with assets exceeding $40.99 billion, and aims to match the performance of the Health Care Select Sector Index [3] Fund Details - The ETF has an annual operating expense ratio of 0.08%, making it the least expensive option in the healthcare ETF space, with a 12-month trailing dividend yield of 1.56% [5] - The fund is fully allocated to the healthcare sector, with top holdings including Eli Lilly + Co (12.97%), Johnson + Johnson, and Abbvie Inc, which together account for approximately 57.14% of total assets [6][7] Performance Metrics - As of December 16, 2025, XLV has returned approximately 14.79% year-to-date and 12.45% over the past year, with a trading range between $128.77 and $158.77 in the last 52 weeks [8] - The ETF has a beta of 0.61 and a standard deviation of 13.38% over the trailing three-year period, indicating a medium risk profile [8] Alternatives - Other healthcare ETFs include iShares Global Healthcare ETF (IXJ) with $4.52 billion in assets and Vanguard Health Care ETF (VHT) with $17.53 billion, each with different expense ratios [11]

Core Insights - Johnson & Johnson (JNJ) has experienced a significant increase of approximately 45% in 2025, which nearly accounts for the total gains made over the past five years [1] Financial Performance - The execution and financial numbers for Johnson & Johnson have been strong, indicating a solid operational performance [1] Growth Potential - There is potential for further growth for Johnson & Johnson, suggesting that the company may continue to expand its market presence and financial performance [1]

Group 1 - Bank of America has raised Johnson & Johnson's target price from $204 to $220 while maintaining a "Neutral" rating [1]

Core Viewpoint - A California court awarded $40 million to two women who claimed their ovarian cancer was linked to prolonged use of Johnson & Johnson's talcum-based baby powder, highlighting the company's alleged knowledge of potential harm without notifying consumers [1][4]. Group 1: Court Ruling and Compensation - The Los Angeles Superior Court jury awarded a total of $40 million, with $18 million to Monica Kent and $22 million to Deborah Schultz and her husband [1][9]. - Both women reported regular use of the baby powder for approximately four decades and underwent significant medical treatments for their ovarian cancer [3]. Group 2: Company Response and Legal Strategy - Johnson & Johnson plans to appeal the ruling, expressing confidence in overturning the verdict based on their historical success in similar cases [2][10]. - The company maintains that its products are safe, asbestos-free, and do not cause cancer, despite facing over 67,000 lawsuits related to talc products [6][11]. Group 3: Historical Context and Ongoing Litigation - The attorney for the plaintiffs stated that Johnson & Johnson was aware of the potential carcinogenic nature of their product since the 1960s and accused the company of suppressing this information [4]. - Johnson & Johnson has attempted to address litigation through bankruptcy, but these attempts have been dismissed by federal courts [7]. - The company has faced substantial verdicts in similar cases, including a notable $4.69 billion award in previous trials [7][8].

Core Insights - Link Cell Therapies has officially launched from stealth mode with a $60 million Series A financing round [1][2] Group 1: Financing Details - The Series A financing was led by Johnson & Johnson through its corporate venture capital organization, Johnson & Johnson Innovation - JJDC, Inc. [2] - Founding investors include Samsara BioCapital and Sheatree Capital, along with participation from Wing Venture Capital and other new strategic and financial investors [2]

Core Insights - Johnson & Johnson (JNJ) received FDA approval for its precision therapy Akeega for a second indication in prostate cancer, specifically for BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC) [2][8] - The approval is based on the phase III AMPLITUDE study, which demonstrated a 54% reduction in the risk of radiographic progression or death with the Akeega-prednisone combination [3][8] - JNJ aims to achieve $50 billion in oncology sales by the end of the decade, with oncology currently accounting for approximately 27% of its total revenues [9][11] Drug Approval and Efficacy - Akeega combines the PARP inhibitor niraparib and the CYP17 inhibitor abiraterone acetate, marking the first FDA-approved precision medicine combination for BRCA2m mCSPC [3][5] - The drug's use has been expanded to an earlier stage of the disease, following its previous approval for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in 2023 [4][8] Financial Performance and Growth Strategy - JNJ's oncology sales rose nearly 21% year over year in the first nine months to $18.52 billion, driven by strong market growth and key products [9] - The company has seen its stock rise 46% this year, outperforming the industry average growth of 16% [6] - JNJ is actively building its oncology pipeline through acquisitions, including a recent agreement to acquire Halda Therapeutics for $3.05 billion [13] Market Position and Future Outlook - The oncology segment's growth is supported by new drug launches, contributing significantly to revenue increases [10][12] - JNJ's ambitious target of $50 billion in oncology sales requires more than doubling its sales from 2024 levels, reflecting confidence in its marketed cancer drugs and pipeline [11][12]